featured
Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With mRCC Treated With Nivolumab Plus Ipilimumab or Cabozantinib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Genitourinary Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib
Clin Genitourin Cancer 2022 Jun 09;[EPub Ahead of Print], R Iacovelli, C Ciccarese, M Maruzzo, F Atzori, L Galli, S Scagliarini, F Massari, E Verzoni, A Cannella, MG Maratta, C Caserta, D Bimabatti, FM Deppieri, M Dessi, F Paolieri, F Riccardi, S Bracarda, U De Giorgi, U Basso, G Tortora, G ProcopioFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.